TY  - GEN
AU  - Bourlière,Marc
AU  - Gordon,Stuart C
AU  - Schiff,Eugene R
AU  - Tran,Tram T
AU  - Ravendhran,Natarajan
AU  - Landis,Charles S
AU  - Hyland,Robert H
AU  - Stamm,Luisa M
AU  - Zhang,Jie
AU  - Dvory-Sobol,Hadas
AU  - Subramanian,G Mani
AU  - Brainard,Diana M
AU  - McHutchison,John G
AU  - Serfaty,Lawrence
AU  - Thompson,Alex J
AU  - Sepe,Thomas E
AU  - Curry,Michael P
AU  - Reddy,K Rajender
AU  - Manns,Michael P
TI  - Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1
SN  - 2468-1253
PY  - 2019///0307
KW  - Aminoisobutyric Acids
KW  - Antiviral Agents
KW  - adverse effects
KW  - Carbamates
KW  - Cyclopropanes
KW  - Drug Combinations
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - genetics
KW  - Hepatitis C, Chronic
KW  - drug therapy
KW  - Heterocyclic Compounds, 4 or More Rings
KW  - Humans
KW  - Lactams, Macrocyclic
KW  - Leucine
KW  - analogs & derivatives
KW  - Macrocyclic Compounds
KW  - Male
KW  - Middle Aged
KW  - Proline
KW  - Quinoxalines
KW  - RNA, Viral
KW  - blood
KW  - Sofosbuvir
KW  - Sulfonamides
KW  - Treatment Failure
KW  - Viral Nonstructural Proteins
KW  - antagonists & inhibitors
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S2468-1253(18)30118-3
ER  -